-o-c-o- Is Part Of A Hetero Ring (e.g., Acetonide, Etc.) Patents (Class 514/174)
-
Publication number: 20140357600Abstract: Described herein are compositions (e.g., a pharmaceutical composition) and methods for controlling the delivery of a therapeutic agent, and their use in the treatment and/or prevention of diseases and disorders.Type: ApplicationFiled: June 6, 2014Publication date: December 4, 2014Applicant: CHEMIC LABORATORIES INC.Inventors: Joseph P. St. Laurent, Scott A. Goodrich, Gerald S. Jones, Jr.
-
Publication number: 20140357607Abstract: The present disclosure generally relates to pharmaceutical corticosteroid compositions, and methods of making the same.Type: ApplicationFiled: June 3, 2014Publication date: December 4, 2014Inventors: Robert Lathrop, David Wade Osborne
-
Publication number: 20140349983Abstract: Provided herein are methods of treating and inducing ulcerative colitis in a subject. Also provided are methods of treating subjects with mild to moderate active ulcerative colitis, including ulcerative proctitis and proctosigmoiditis. Also provided are methods of administering budesonide to a subject to treat ulcerative colitis, including ulcerative proctitis and proctosigmoiditis.Type: ApplicationFiled: July 31, 2014Publication date: November 27, 2014Inventors: William P. Forbes, Enoch Bortey, Craig Paterson, Pam Golden
-
Publication number: 20140348787Abstract: Compositions and methods for treating ear infections are disclosed. More specifically, these methods may refer to treatment of internal otitis using an otic composition, such as otic gel for animals and humans. Poloxamer otic gel may be in liquid state at room temperature and may change to gel at about temperature (64° F.) as poloxamer otic gel reaches body temperature, because of the thermo-reversible properties. Consequently, poloxamer otic gel may be an effective treatment in animals and humans, where poloxamer otic gel may reach otitis affected site and remain there for a longer period of time. Additionally, poloxamer otic gel may include APIs such as antifungals, antibiotics and corticosteroids, among others. Furthermore, poloxamer otic gel may be instilled inside the ear, employing calibrated delivery device into the vertical ear canal in order to reach the horizontal ear canal, without puncturing the tympanic membrane.Type: ApplicationFiled: May 22, 2013Publication date: November 27, 2014Applicant: PROFESSIONAL COMPOUNDING CENTERS OF AMERICAInventor: Chris V. Simmons
-
Publication number: 20140349982Abstract: Provided herein are methods of treating and inducing ulcerative colitis in a subject. Also provided are methods of treating subjects with mild to moderate active ulcerative colitis, including ulcerative proctitis and proctosigmoiditis. Also provided are methods of administering budesonide to a subject to treat ulcerative colitis, including ulcerative proctitis and proctosigmoiditis.Type: ApplicationFiled: May 20, 2014Publication date: November 27, 2014Applicant: Salix Pharmaceuticals, Inc.Inventors: William Forbes, Enoch Bortey, Craig Paterson, Pam Golden
-
Publication number: 20140336162Abstract: This invention provides for using a locally delivered low dose of a corticosteroid to treat pain caused by any inflammatory disease including sciatica, herniated disc, stenosis, mylopathy, low back pain, facet pain, osteoarthritis, rheumatoid arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug depot.Type: ApplicationFiled: July 28, 2014Publication date: November 13, 2014Inventors: William F. McKay, John Myers Zanella, Christopher M. Hobot
-
Publication number: 20140336160Abstract: This invention relates to novel glucocorticoid receptor agonists of formula (I): and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to their combination with one or more other therapeutic agents, as well as to their use for the treatment of a number of inflammatory and allergic diseases, disorders and conditions.Type: ApplicationFiled: July 23, 2014Publication date: November 13, 2014Inventors: Paul Alan Glossop, David Simon Millan, David Anthony Price
-
Publication number: 20140336161Abstract: The potency of a topical corticosteroid in a pharmaceutical formulation is maintained even when the concentration of the corticosteroid is substantially reduced by providing the corticosteroid in a formulation containing a liquid oil component that includes a dicarboxylic acid ester and/or a monocarboxylic acid ester.Type: ApplicationFiled: July 24, 2014Publication date: November 13, 2014Inventors: Arturo Angel, Gordon Dow
-
Patent number: 8883768Abstract: Effective treatments for protecting against undesirable macrophage activity are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce or prevent macrophage activity. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to prevent transplant rejection for at least thirty days. In some embodiments, the relief can be for at least sixty days, or up to ninety days.Type: GrantFiled: February 26, 2009Date of Patent: November 11, 2014Assignee: Warsaw Orthopedic, Inc.Inventor: Vanja Margareta King
-
Publication number: 20140323451Abstract: Described here are methods for the treatment of respiratory conditions using nebulized corticosteroids. The methods administer a dose of corticosteroid twice a day or more with nebulization times of 5 minutes or less. The faster nebulization times improve patient compliance. The methods also employ a lower corticosteroid dose while achieving therapeutic efficacy similar to commercially available formulations. This results in improved patient safety by reducing the systemic exposure of the corticosteroid.Type: ApplicationFiled: July 8, 2014Publication date: October 30, 2014Inventors: STEPHEN B. SHREWSBURY, PAUL S. USTER, ANDREW P. BOSCO, THOMAS A. ARMER
-
Publication number: 20140302143Abstract: The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating.Type: ApplicationFiled: June 18, 2014Publication date: October 9, 2014Applicant: COSMO TECHNOLOGIES LIMITEDInventors: Roberto VILLA, Massimo PEDRANI, Mauro AJANI, Lorenzo FOSSATI
-
Publication number: 20140302139Abstract: The invention relates to an oral pharmaceutical composition comprising an active agent, a macroscopically homogeneous structure and a gastro-resistant coating. The macroscopically homogeneous structure comprises at least one hydrophilic compound and at least one lipophilic compound and/or at least one amphiphilic compound. The macroscopically homogeneous structure controls the release of the active ingredient, and the gastro-resistant film prevents release of the active agent in the stomach.Type: ApplicationFiled: June 18, 2014Publication date: October 9, 2014Applicant: COSMO TECHNOLOGIES LIMITEDInventors: Roberto VILLA, Massimo PEDRANI, Mauro AJANI, Lorenzo FOSSATI
-
Publication number: 20140296191Abstract: The present invention relates to pharmaceutical compositions of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle or as a solvent system in preparation of such pharmaceutical compositions. The pharmaceutical compositions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formulations containing such pharmaceutical actives and are suitable for use as injectables for intravenous and intramuscular administration, as well as for use as a preformed solution/liquid for filling in and preparation of capsules, tablets, nasal sprays, gargles, dermal applications, gels, topicals, liquid oral dosage forms and other dosage forms.Type: ApplicationFiled: April 2, 2014Publication date: October 2, 2014Applicant: THEMIS MEDICARE LIMITEDInventors: Dinesh Shantilal PATEL, Sachin Dinesh PATEL, Shashikant Prabhudas KURANI, Madhavlal Govindlal PATEL
-
Publication number: 20140274982Abstract: Provided herein are compositions and methods for treating or preventing a skin disease or skin condition on the skin of a subject by administering a topical flunisolide composition comprising a therapeutically effective amount of flunisolide and a solubilizing agent that solubilizes the flunisolide.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Medicis Pharmaceutical CorporationInventors: Douglas Anthony Bakan, Steven B. Newhard, Nilendu Sen, Amol Subhash Mandhare, Tushar Deoram Jadhav, Mukesh Kumar
-
Patent number: 8822439Abstract: This invention relates to novel glucocorticoid receptor agonists of formula (I): and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to their combination with one or more other therapeutic agents, as well as to their use for the treatment of a number of inflammatory and allergic diseases, disorders and conditions.Type: GrantFiled: November 24, 2008Date of Patent: September 2, 2014Assignee: Pfizer Inc.Inventors: Paul Alan Glossop, David Simon Millan, David Anthony Price
-
Publication number: 20140242170Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: December 16, 2013Publication date: August 28, 2014Applicant: FLEXION THERAPEUTICS, INC.Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20140234225Abstract: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.Type: ApplicationFiled: February 17, 2014Publication date: August 21, 2014Applicant: Alkermes Pharma Ireland LimitedInventors: Christian F. Wertz, Niels P. Ryde
-
Publication number: 20140234418Abstract: A method for treating intestinal fibrosis in a subject, comprising enterally administering a steroid to the subject. The steroid may be in a multiple minibead formulation.Type: ApplicationFiled: February 20, 2014Publication date: August 21, 2014Applicant: Sigmoid Pharma LimitedInventors: Ivan Coulter, Vincenzo Aversa
-
Patent number: 8802128Abstract: Biocompatible intraocular implant systems are formulated for discontinuous or intermittent release of therapeutic levels of a therapeutic agent (such as a steroid) to minimize development of side effects associated with continuous or long term use of such agent. The implant system may comprise one or more implant, and preferably, although not necessarily, also contains an auxiliary agent having an activity effective to lessen at least one side effect associated with said therapeutic agent compared to the use of an otherwise identical implant system lacking said auxiliary agent. The implants containing the therapeutic agent and auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the ocular side effects otherwise accompanying the use of such therapeutic agent.Type: GrantFiled: July 21, 2006Date of Patent: August 12, 2014Assignee: Allergan, Inc.Inventors: Michael R. Robinson, Scott M. Whitcup
-
Publication number: 20140212504Abstract: Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.Type: ApplicationFiled: April 2, 2014Publication date: July 31, 2014Inventors: Jeffry G. WEERS, Thomas E. TARARA, Luis A. DELLAMARY, Jean G. RIESS, Ernest G. SCHUTT
-
Patent number: 8785425Abstract: The invention provides 11?-hydroxyandrosta-4-ene-3-one compounds of Formula I, or physiologically acceptable salts or solvates thereof: wherein R4 represents a moiety selected from a group consisting of (A), (B) and (C), with a proviso that when R4 represents moiety (C), Z is S:Type: GrantFiled: July 25, 2008Date of Patent: July 22, 2014Assignee: Sun Pharma Advanced Research Company Ltd.Inventors: Jiten Ranchhodbhai Patel, Gopalkumar Chimanlal Patel, Gaurav Sanjivkumar Sheth, Samir Rameshchandra Shah, Sanjay Nandlal Mandhane, Trinadha Rao Chitturi, Rajamannar Thennati
-
Patent number: 8784893Abstract: Disclosed in the present application are compositions comprising a bioresorbable polymer matrix and a bio active agent, wherein the bioactive agent is dispersed within polymer matrix as a solid. Also provided herein are methods for preparing a bioactive agent formulation, wherein the agent is present in a solid form and, wherein the agent is occluded into a polymeric matrix by polymerization of polymer matrix precursors or by self assembly of the polymer.Type: GrantFiled: February 5, 2008Date of Patent: July 22, 2014Assignee: Carbylan Therapeutics, Inc.Inventors: George Daniloff, David Gravett, Robert C. Spiro
-
Publication number: 20140199232Abstract: Disclosure of methods and compositions related to chemical conjugations to nanoparticles of polysaccharides cross-linked to poloxamers as well as nano-sized colloids comprised of polysaccharides and poloxamers. The nanoparticles may be produced by various methods including inverse miniemulsion polymerization processes which create nanogels of desired size, shape, and stability for controlled therapeutic drug delivery, imaging, and theragnostic applications.Type: ApplicationFiled: July 16, 2013Publication date: July 17, 2014Applicant: NANODERM SCIENCES, INC.Inventors: Richard A. Winchurch, Roy R. Yeoman
-
Patent number: 8771744Abstract: The invention provides a process for increasing the crystallinity of at least one solid material which is less than 100% crystalline, comprising applying ultrasound to the substantially dry solid material.Type: GrantFiled: October 20, 2010Date of Patent: July 8, 2014Assignee: Prosonix LimitedInventors: Graham Ruecroft, Dipesh Parikh
-
Publication number: 20140187523Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.Type: ApplicationFiled: January 3, 2014Publication date: July 3, 2014Applicants: Meritage Pharma, Inc., The Regents of the University of CaliforniaInventors: Ranjan Dohil, John Bastian, Seema Aceves, Elaine Phillips, Malcolm Hill
-
Publication number: 20140187517Abstract: The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions.Type: ApplicationFiled: March 5, 2014Publication date: July 3, 2014Applicants: SANTARUS, INC., COSMO TECHNOLOGIES LIMITEDInventors: Gerald Thomas PROEHL, Wendell WIERENGA, Michael Fangching HUANG, Emerson David BALLARD, II, Luigi MORO
-
Publication number: 20140179651Abstract: The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative or salt thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), Summer Pasture Associated Obstructive Pulmonary disease (SPAOPD), and inflammatory airway disease (IAD).Type: ApplicationFiled: December 18, 2013Publication date: June 26, 2014Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Balazs ALBRECHT, Michael AVEN, Janine LAMAR, Ingo LANG
-
Publication number: 20140179650Abstract: The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to a pharmaceutical (medicament) formulation of glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative thereof.Type: ApplicationFiled: December 18, 2013Publication date: June 26, 2014Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Michael AVEN, Balazs ALBRECHT, Benjamin FRANZMANN, Matthias HAUSMANN, Janine LAMAR, Ingo LANG
-
Publication number: 20140154321Abstract: An injectable drug delivery includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as “coatings,” “skins,” or “outer layers”). In certain embodiments, the device is formed by extruding or otherwise preforming a polymeric skin for a drug core. The drug core may be co-extruded with the skin, or inserted into the skin after the skin has been extruded, and possibly cured. In other embodiments, the drug core may be coated with one or more polymer coatings. These techniques may be usefully applied to fabricate devices having a wide array of drug formulations and skins that can be selected to control the release rate profile and various other properties of the drugs in the drug core in a form suitable for injection using standard or non-standard gauge needles.Type: ApplicationFiled: November 27, 2013Publication date: June 5, 2014Applicant: PSIVIDA US, INC.Inventor: Paul Ashton
-
Publication number: 20140147506Abstract: Pharmaceutically engineered aerosols (e.g. submicrometer and nano-particles and droplets) containing a hygroscopic growth excipient or agent are employed to improve the delivery of respiratory aerosols to the lung. Inclusion of the hygroscopic agent results in near zero depositional loss in the nose-mouth-throat regions and near 100% deposition of the aerosol in the lung. Targeting of the aerosol to specific lung depths is also possible. In addition, methods and apparatuses for delivering aerosols to the lung are provided. The aerosol is delivered to one nostril of a patient while a relatively high humidity gaseous carrier is delivered to the other nostril, resulting in post-nasopharyngeal growth of the aerosol to a size that promotes deposition in the lung.Type: ApplicationFiled: January 29, 2014Publication date: May 29, 2014Applicant: Virginia Commonwealth UniversityInventors: Philip Worth Longest, Michael Hindle
-
Publication number: 20140148424Abstract: The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment of a variety of disease conditions comprise a mass of biocompatible particles comprising an active agent, and a hydrogenated starch hydrosylate (HSH). The improvement over the prior art comprises the presence of HSH in the pharmaceutical formulation. The invention further relates to a method of treating diseases comprising administering the pharmaceutical formulations of the present invention to the respiratory system of a patient in need of treatment.Type: ApplicationFiled: November 19, 2013Publication date: May 29, 2014Applicant: Civitas Therapeutics, Inc.Inventors: Charles D. Blizzard, Michael M. Lipp, Kevin L. Ward, Rachel Ryznal, Daniel Leblanc, Mark Tracy, Rebecca Martin
-
Publication number: 20140135302Abstract: Methods, compositions, and kits for predicting whether a subject with chronic obstructive pulmonary disease (COPD) or at risk of developing COPD is likely to have progressive COPD are provided. Methods, compositions, and kits for predicting whether lung function is likely to decline in a subject with COPD or at risk for developing COPD are also provided.Type: ApplicationFiled: November 7, 2013Publication date: May 15, 2014Applicant: SOMALOGIC, INC.Inventors: Malti P. Nikrad, Stuart G. Field, Stephen Alaric Williams, Alex A.E. Stewart, Rachel M. Ostroff, Rosalynn Dianne Gill
-
Publication number: 20140120165Abstract: A new particle morphology of glucocorticosteroids is described. The forms have a particle morphology that is particularly well suited for use in an inhaled corticosteroid drug suspension formulation for delivery from a next generation nebulizer device. Use of the new glucocorticosteroid particles enables enhanced drug delivery efficiency and increased residence time of the delivered drug in the lungs. New methods for producing glucocorticosteroid particles having these specific particle morphologies are also described. The methods provide a simplified, reproducible and scalable particle formation process that can produce glucocorticosteroid particles having a narrow particle size and shape distribution, a low surface energy, a low aspect ratio, uniform particle morphology and a reduced specific surface area.Type: ApplicationFiled: October 2, 2013Publication date: May 1, 2014Applicant: MAP PHARMACEUTICALS, INC.Inventors: Libo Wu, Wiwik Watanabe, Jian Zhang
-
Patent number: 8680073Abstract: A pharmaceutical composition comprising in admixture a hyaluronic acid related component (HARC) and a pharmaceutically effective amount of triamcinolone hexacetonide (TAH). The composition is stable in an accelerated shelf life test in which the composition is heated to 80° C. for 24 hours.Type: GrantFiled: August 23, 2012Date of Patent: March 25, 2014Assignee: Genzyme CorporationInventors: Grace Chang, Elizabeth Voschin, Li-Ping Yu, Eugene Skrabut
-
Patent number: 8679545Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.Type: GrantFiled: November 12, 2008Date of Patent: March 25, 2014Assignees: The Regents of the University of California, Meritage Pharma, Inc.Inventors: Ranjan Dohil, John Bastian, Seema Aceves
-
Patent number: 8658128Abstract: This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.Type: GrantFiled: February 2, 2012Date of Patent: February 25, 2014Assignee: Pop Test Cortisol LLCInventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
-
Publication number: 20140051671Abstract: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.Type: ApplicationFiled: October 28, 2013Publication date: February 20, 2014Applicant: Allergan, Inc.Inventors: Robert T. Lyons, James N. Chang, John T. Trogden, Scott Whitcup
-
Patent number: 8652464Abstract: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.Type: GrantFiled: December 4, 2012Date of Patent: February 18, 2014Assignee: Alkermes Pharma Ireland LimitedInventors: Christian F. Wertz, Niels P. Ryde
-
Publication number: 20140030351Abstract: The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.Type: ApplicationFiled: September 27, 2013Publication date: January 30, 2014Applicant: BIND Therapeutics, Inc.Inventors: Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
-
Publication number: 20140030224Abstract: The present invention relates to methods and pharmaceutical compositions for inhibiting influenza virus replication. More particularly, the present invention relates to a compound selected from the group consisting of Gemcitabine, Obatoclax Mesylate, Docetaxel, HA-14, Alsterpaullone, GSK3B inhibitor VIII, GSK3B inhibitor XV, Indirubin 3?- monoxime, L glutathione reduced, Fluocinolone acetonide, Tirofiban, Topotecan hydrochloride, Clofarabine, Vinblastine, Menadione Crystalline and derivatives or analogues thereof for use in the treatment of an influenza infection in a subject in need thereof.Type: ApplicationFiled: April 10, 2012Publication date: January 30, 2014Applicant: UNIVERSITÉ CLAUDE BERNARD - LYON 1Inventors: Vincent Lotteau, Benoit De Chassey, Patrice Andre, Laurene Meyniel-Schicklin, Anne Aublin-Gex
-
Publication number: 20140030340Abstract: A method for preparing poorly water soluble drug particles is disclosed. The method comprises dissolving a drug in at least one organic solvent to form a drug/organic mixture, spraying the drug/organic mixture into an aqueous solution and concurrently evaporating the organic solvent in the presence of the aqueous solution to form an aqueous dispersion of the drug particles. The resulting drug particles are in the nanometer to micrometer size range and show enhanced dissolution rates and reduced crystallinity when compared to the unprocessed drug. The present invention additionally contemplates products and processes for new drug formulations of insoluble drug particles having high dissolution rates and extremely high drug-to-excipient ratios.Type: ApplicationFiled: October 3, 2013Publication date: January 30, 2014Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Keith P. Johnston, Robert O. Williams, III, Xiaoxia Chen
-
Publication number: 20140030233Abstract: This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc. The present invention further relates to the use of cortisol blockers (GR antagonists) for wound healing and transplants, the prevention or treatment of stress induced osteoporosis and the rapid healing of bone related injuries, and regenerative therapy.Type: ApplicationFiled: March 15, 2013Publication date: January 30, 2014Applicant: POP TEST CORTISOL LLCInventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
-
Publication number: 20140005132Abstract: The invention provides compounds of formula I, II, III, or IV: wherein R1 to R11, X, and Y have any of the values defined in the specification. The compounds inhibit Na, K-ATPase ?4 and are useful as contraceptive agents.Type: ApplicationFiled: July 1, 2013Publication date: January 2, 2014Applicants: REGENTS OF THE UNIVERSITY OF MINNESOTA, THE UNIVERSITY OF KANSASInventors: Gustavo Blanco, Gunda I. Georg, Shameem Sultana Syeda
-
Publication number: 20130338127Abstract: The present invention is drawn to formulations and related methods for treating dermatitis or psoriasis. The formulation can include triamcinolone acetonide, a polymer selected from the group of a poly(2-hydroxyalkylacrylate), a poly(2-hydroxyalkylmethacrylate), and combinations thereof. The formulation also includes a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent.Type: ApplicationFiled: May 4, 2011Publication date: December 19, 2013Applicant: Nuvo Research Inc.Inventors: Hyder Aliyar, Jie Zhang
-
Publication number: 20130323179Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.Type: ApplicationFiled: May 3, 2013Publication date: December 5, 2013Applicant: Johns Hopkins University, TheInventors: Alexey Popov, Elizabeth M. Enlow, James Bourassa, Colin R. Gardner, Hongming Chen, Laura M. Ensign, Samuel K. Lai, Tao Yu, Justin Hanes, Ming Yang
-
Publication number: 20130323301Abstract: This disclosure relates to replication competent viral vectors for treating cell proliferative disorders. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.Type: ApplicationFiled: October 31, 2011Publication date: December 5, 2013Applicant: TOCAGEN INC.Inventors: Harry E. Gruber, Douglas J. Jolly, Derek G. Ostertag, Ryan S. Burnett, Amy H. Lin, Tiffany Huang, Joan M. Robbins
-
Publication number: 20130316006Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.Type: ApplicationFiled: May 3, 2013Publication date: November 28, 2013Applicant: Kala Pharmaceuticals, Inc.Inventor: Kala Pharmaceuticals, Inc.
-
Publication number: 20130303473Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.Type: ApplicationFiled: November 10, 2011Publication date: November 14, 2013Applicant: NOVALIQ GmbHInventor: Clive G. Wilson
-
Publication number: 20130303498Abstract: An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.Type: ApplicationFiled: November 14, 2012Publication date: November 14, 2013Inventors: James D. PIPKIN, Rupert O. ZIMMERER, Diane O. THOMPSON, Gerold L. MOSHER
-
Publication number: 20130303499Abstract: The invention relates to nitrooxy derivatives of fluocinolone acetonide, triamcinolone acetonide, betamethasone and beclomethasone, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for treating diabetic macular edema, diabetic retinopathy, macular degeneration, age-related macular degeneration and other diseases of retina and macula lutea.Type: ApplicationFiled: July 19, 2013Publication date: November 14, 2013Inventors: Francesca BENEDINI, Annalisa BONFANTI, Valerio CHIROLI, Rebecca STEELE, Ennio ONGINI, Stefano BIONDI